Trial Comparing Lower vs. Higher Platelet Transfusion Thresholds in Extremely Preterm Infants Born Between 23 and 26 Weeks to Improve Survival and Reduce Bleeding

What this Trial Is About

Researchers are evaluating whether using a lower platelet transfusion threshold compared to a higher threshold improves survival without major or severe bleeding in extremely preterm infants born between 23 07 and 26 67 weeks gestation. This study focuses on infants in neonatal intensive care who often experience thrombocytopenia, a condition where platelet counts are low. The goal is to find the best platelet transfusion practice to reduce bleeding risks and improve outcomes in this vulnerable group. The study randomly assigns infants to one of two groups. One group follows a higher platelet transfusion threshold during the first week of life and then a moderate threshold afterward, while the other group follows lower thresholds during these periods. Platelet transfusions are given at a dose of 10 mlkg over 60 to 120 minutes. The treatment protocol continues until infants reach 40 07 weeks postmenstrual age. Participants are monitored from randomization until 40 07 weeks postmenstrual age or earlier if discharged or transferred. Researchers will collect data on survival without major bleeding, number of platelet transfusions, and other health outcomes like bronchopulmonary dysplasia and retinopathy of prematurity. The total participation duration averages about 98 days postnatal age, with safety and health closely observed throughout the study.

Neonatal Platelet Transfusion Threshold Trial